[go: up one dir, main page]

WO2009108372A3 - Antibodies as t cell receptor mimics, methods of production and uses thereof - Google Patents

Antibodies as t cell receptor mimics, methods of production and uses thereof Download PDF

Info

Publication number
WO2009108372A3
WO2009108372A3 PCT/US2009/001290 US2009001290W WO2009108372A3 WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3 US 2009001290 W US2009001290 W US 2009001290W WO 2009108372 A3 WO2009108372 A3 WO 2009108372A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibodies
methods
production
cell receptor
receptor mimics
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/001290
Other languages
French (fr)
Other versions
WO2009108372A2 (en
Inventor
Jon A. Weidanz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RECEPTOR LOGIC Inc
Original Assignee
RECEPTOR LOGIC Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RECEPTOR LOGIC Inc filed Critical RECEPTOR LOGIC Inc
Priority to EP09715242A priority Critical patent/EP2262834A4/en
Publication of WO2009108372A2 publication Critical patent/WO2009108372A2/en
Publication of WO2009108372A3 publication Critical patent/WO2009108372A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The presently disclosed and claimed invention relates to a methodology of producing and utilizing antibodies that recognize peptides associated with a tumorigenic or disease state, wherein the peptides are displayed in the context of HLA molecules. These antibodies may be utilized in therapeutic methods of mediating cell lysis.
PCT/US2009/001290 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof Ceased WO2009108372A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP09715242A EP2262834A4 (en) 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US6732808P 2008-02-27 2008-02-27
US61/067,328 2008-02-27
US19187108P 2008-09-12 2008-09-12
US61/191,871 2008-09-12

Publications (2)

Publication Number Publication Date
WO2009108372A2 WO2009108372A2 (en) 2009-09-03
WO2009108372A3 true WO2009108372A3 (en) 2009-11-05

Family

ID=41016658

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/001290 Ceased WO2009108372A2 (en) 2008-02-27 2009-02-27 Antibodies as t cell receptor mimics, methods of production and uses thereof

Country Status (2)

Country Link
EP (1) EP2262834A4 (en)
WO (1) WO2009108372A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831336C (en) 2011-04-01 2019-10-01 David A. Scheinberg T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
GB201501017D0 (en) * 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
HRP20211754T1 (en) 2014-12-23 2022-03-04 Immatics Biotechnologies Gmbh NEW PEPTIDES AND COMBINATIONS OF PEPTIDS FOR USE IN IMMUNOTHERAPY AGAINST HEPATOCELLULAR CARCINOMA (HCC) AND OTHER CANCERS
AU2016243026B2 (en) 2015-04-03 2022-03-31 Eureka Therapeutics, Inc. Constructs targeting AFP peptide/MHC complexes and uses thereof
EP4153633A1 (en) 2020-05-19 2023-03-29 Amgen Inc. Mageb2 binding constructs

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2662798A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as t cell receptor mimics, methods of production and uses thereof
AU2007254859A1 (en) * 2006-06-01 2007-12-13 Receptor Logic, Ltd Antibodies as T cell receptor mimics, methods of production and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060034850A1 (en) * 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20070092530A1 (en) * 2004-05-27 2007-04-26 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
US20090042285A1 (en) * 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ANETTE STRYHN ET AL.: "Shared fine specificity between T-cell receptors and an antibody recognizing a peptide/major histocompatibility class I complex", PROC. NATL. ACAD. SCI. USA, vol. 93, September 1996 (1996-09-01), pages 10338 - 10342, XP008143529 *
BINH ET AL.: "Epitopes of the class I major histocompatibility complex (MHC-I) recognized in the syngeneic or allogeneic context predominantly linked to antigenic peptide loading to its binding groove", BRITISH SOCIETY FOR IMMUNOLOGY, CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 145, 2006, pages 372 - 379, XP008143527 *
CYRIL J. COHEN ET AL.: "Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions", J. MOL. RECOGNITION., vol. 16, 2003, pages 324 - 332, XP008050078 *
DENKBERG ET AL.: "Recombinant antibodies with T-cell receptor-like specificity: Novel tools to study MHC class I presentation", AUTOIMMUNITY REVIEWS, vol. 5, 2006, pages 252 - 257, XP024977451 *
DOO HYUN CHUNG ET AL.: "Competitive Inhibition In Vivo and Skewing of the T Cell Repertoire of Antigen-Specific CTL Priming by an Anti-Peptide-MHC Monoclonal Antibody", THE JOURNAL OF IMMUNOLOGY, vol. 167, 2001, pages 699 - 707, XP002903695 *
See also references of EP2262834A4 *
WEIDANZ ET AL.: "Development and implementation of a direct detection, quantitation and validation system for class I MHC self-peptide epitopes", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 318, 2007, pages 47 - 58, XP005820135 *

Also Published As

Publication number Publication date
EP2262834A2 (en) 2010-12-22
WO2009108372A2 (en) 2009-09-03
EP2262834A4 (en) 2011-08-17

Similar Documents

Publication Publication Date Title
IL207449A0 (en) Genetically modified cyanobacteria, methods of producing the same and methods of producing ethanol utilizing the same
IL216861A (en) Nucleic acids encoding polypeptides that bind to activine, gdf8 or gdf11, cultured cells comprising them, polypeptides, pharmaceutical preparations and uses thereof
IL195470A0 (en) Antibodies as t cell receptor mimics, methods of production and uses thereof
WO2010117957A3 (en) Methods and materials for delivering molecules
WO2013152059A8 (en) Multicolored ph-activatable fluorescence nanoplatform
WO2013151666A3 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
HK1206601A1 (en) Modified polynucleotides for the production of biologics and proteins associated with human disease
NZ593314A (en) Dual variable domain immunoglobulins and uses thereof
IL206715A (en) Monoclonal anti mif antibodies, pharmaceutical compositions comprising them, their uses and methods of producing them
HK1214831A1 (en) Novel fusion molecules and uses thereof
WO2011056644A3 (en) Anti-glp-1r antibodies and their uses
ZA200908384B (en) Methods of modifying antibodies, and modified antibodies with improved functional properties
MY161909A (en) Anti-her3 antibodies and uses thereof
WO2014012001A3 (en) Use of cart19 to deplete normal b cells to induce tolerance
WO2010040508A8 (en) Bispecific anti-vegf/anti-ang-2 antibodies
WO2011131746A3 (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2636642A4 (en) Cnt dispersion liquid, cnt compact, cnt composition, cnt assembly, and method for producing each
WO2012088290A3 (en) Tri-variable domain binding proteins and uses thereof
IL212066A (en) Anti cxcr4 antibodies, compositions comprising them, processes for their production and selection and use thereof
EP2334330A4 (en) Anti-cd147 antibodies, methods, and uses
WO2012024452A3 (en) Modified relaxin polypeptides and their uses
PT2510012T (en) Anti-c4.4a antibodies and uses thereof
HK1197273A1 (en) Methods and materials related to ovarian cancer
WO2010136483A3 (en) Antigen-binding proteins
WO2012046084A3 (en) Short rna molecules

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09715242

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009715242

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE